Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Chengdu Kanghong Pharmaceutical Gets US FDA Nod for Clinical Trial of KH658 for Wet AMD

Fineline Cube Apr 29, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a leading pharmaceutical company based in China,...

Company Drug

CARsgen Therapeutics Submits CAPA Report to US FDA Following Clinical Hold

Fineline Cube Apr 29, 2024

CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...

Company Drug

Yantai Dongcheng Pharmaceutical Receives NMPA Approval for Advanced Solid Tumor Therapy

Fineline Cube Apr 29, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China,...

Company Drug

Keymed Biosciences’ Stapokibart Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Study

Fineline Cube Apr 29, 2024

China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that its IL-4Rα monoclonal antibody...

Company Deals

Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China

Fineline Cube Apr 28, 2024

Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering...

Company Drug

Pfizer’s Gene Therapy Beqvez Wins FDA Nod for Moderate-to-Severe Hemophilia B

Fineline Cube Apr 28, 2024

The US Food and Drug Administration (FDA) has granted marketing authorization to Pfizer (NYSE: PFE)...

Company Drug

Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval

Fineline Cube Apr 28, 2024

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...

Company Drug

HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe

Fineline Cube Apr 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...

Policy / Regulatory

China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement

Fineline Cube Apr 28, 2024

The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...

Company Drug

Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment

Fineline Cube Apr 28, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...

Company Medical Device

Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 28, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023,...

Company

United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships

Fineline Cube Apr 28, 2024

Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year...

Company Drug

AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial

Fineline Cube Apr 28, 2024

AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...

Company Policy / Regulatory

Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations

Fineline Cube Apr 28, 2024

Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...

Company Deals

Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation

Fineline Cube Apr 28, 2024

China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...

Company Deals

AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China

Fineline Cube Apr 28, 2024

Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...

Company

Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups

Fineline Cube Apr 28, 2024

Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...

Company

AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I

Fineline Cube Apr 26, 2024

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results...

Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion

Fineline Cube Apr 26, 2024

China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...

Company Deals

Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million

Fineline Cube Apr 26, 2024

Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...

Posts pagination

1 … 420 421 422 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.